secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunoGen, Inc. (—)
CIK:        0000855654
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001104659-24-013712
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunoGen acquired by AbbVie for $31.26/share in $10.1B deal completed Feb 12, 2024
--------------------------------------------------------------------------------

- Shareholders received $31.26 per share cash; total equity value ~$10.1B.
- ImmunoGen stock ceased trading on Nasdaq; delisting and deregistration initiated.
- All outstanding stock options and RSUs vested and converted to cash at $31.26/share.
- Board of directors resigned; new directors appointed by AbbVie effective at close.
- Loan agreement with BioPharma Credit repaid in full; security interests released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/855654/000110465924013712/0001104659-24-013712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/855654/000110465924013712/tm245856d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-013712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer